Grifols (GIFLF) Cash from Financing Activities (2010 - 2020)

Grifols (GIFLF) reported Cash from Financing Activities of -$121.5 million for Q1 2020, down 93.07% on a YoY basis from -$1.8 billion in Q2 2019, and up 54.2% quarter-over-quarter from -$265.2 million in Q4 2019.

Grifols (GIFLF) Cash from Financing Activities (2010 - 2020) Analysis & Trends

Grifols has reported Cash from Financing Activities for 10 years, with the latest figure at -$121.5 million in Q1 2020.

  • For the quarter ending Q1 2020, Cash from Financing Activities fell 93.07% year-over-year to -$121.5 million; the trailing twelve-month figure through Mar 2020 stood at -$356.2 million (down 120.86% YoY), and the FY2025 full-year result was -$615.8 million, up 57.6% from the prior year.
  • Cash from Financing Activities for Q1 2020 stood at -$121.5 million, up from -$265.2 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $1.8 billion in Q4 2017, with the low at -$265.2 million in Q4 2019.
  • Historically, Cash from Financing Activities has averaged $236.6 million across 5 years, with a median of -$62.9 million in 2019.
  • Annual changes were most pronounced in 2017 — Cash from Financing Activities jumped 1301.8% — and 2019, when it tumbled 503.89%.
  • Grifols' Cash from Financing Activities stood at -$146.6 million in 2016, then soared by 1301.8% to $1.8 billion in 2017, then slumped by 94.7% to $93.4 million in 2018, then slumped by 383.88% to -$265.2 million in 2019, then soared by 54.2% to -$121.5 million in 2020.
  • The last three Cash from Financing Activities figures came in at -$121.5 million (Q1 2020), -$265.2 million (Q4 2019), and -$62.9 million (Q1 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn 366.70 Mn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn -3.47 Bn
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn 530.00 Mn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn 919.00 Mn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn -2.98 Bn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn 1.44 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn -4.24 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn -2.86 Bn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn -1.56 Bn
10 Grifols - - - -

Historic Data

Download Data
DateValue
Mar 31, 2020 -121.48 Mn
Mar 31, 2020 -121.48 Mn
Dec 31, 2019 -265.22 Mn
Dec 31, 2019 -265.22 Mn
Mar 31, 2019 -62.92 Mn
Mar 31, 2019 -62.92 Mn
Dec 31, 2018 93.43 Mn
Dec 31, 2018 93.43 Mn
Jun 30, 2018 -207.36 Mn
Jun 30, 2018 -207.36 Mn
Mar 31, 2018 15.58 Mn
Mar 31, 2018 15.58 Mn
Dec 31, 2017 1.76 Bn
Dec 31, 2017 1.76 Bn
Jun 30, 2017 -97.45 Mn
Jun 30, 2017 -97.45 Mn
Mar 31, 2017 1.67 Bn
Mar 31, 2017 1.67 Bn
Dec 31, 2016 -146.57 Mn
Dec 31, 2016 -146.57 Mn